Long-Term Outcomes of S-1 Combined With Low-Dose Docetaxel as Neoadjuvant Chemotherapy (N-1 Study, Phase II Trial) in Patients With Operable Breast Cancer.
Sasa S, Inoue H, Nakagawa M, Toba H, Goto M, Okumura K, Misaki M, Inui T, Yukishige S, Nishisho A, Hino N, Kanematsu M, Bando Y, Uehara H, Tangoku A, Takizawa H.
Sasa S, et al. Among authors: kanematsu m.
Clin Breast Cancer. 2024 Jul;24(5):e350-e359.e2. doi: 10.1016/j.clbc.2024.02.014. Epub 2024 Feb 22.
Clin Breast Cancer. 2024.
PMID: 38462397
Clinical Trial.